Chapin Davis Inc. Takes Position in DaVita Inc. $DVA

Chapin Davis Inc. purchased a new stake in shares of DaVita Inc. (NYSE:DVA) in the second quarter, HoldingsChannel.com reports. The firm purchased 4,548 shares of the company’s stock, valued at approximately $1,012,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Berkshire Hathaway Inc purchased a new stake in shares of DaVita during the second quarter worth about $6,425,269,000. BlackRock Inc. purchased a new position in DaVita in the second quarter valued at about $547,520,000. Invesco Ltd. grew its stake in DaVita by 2.0% during the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock valued at $223,122,000 after purchasing an additional 32,358 shares in the last quarter. Morgan Stanley grew its stake in DaVita by 5.1% during the 4th quarter. Morgan Stanley now owns 1,477,045 shares of the company’s stock valued at $167,807,000 after purchasing an additional 71,156 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in DaVita by 114.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after purchasing an additional 636,191 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Trading Up 1.0%

Shares of NYSE DVA opened at $180.72 on Friday. The company has a market capitalization of $11.53 billion, a price-to-earnings ratio of 14.79, a price-to-earnings-growth ratio of 0.46 and a beta of 0.88. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $247.49. The business has a 50 day simple moving average of $211.96 and a 200-day simple moving average of $183.05.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.88 by $0.14. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the business posted $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts predict that DaVita Inc. will post 14.57 earnings per share for the current year.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on DVA. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $265.00 target price on shares of DaVita in a research note on Wednesday, August 5th. Barclays increased their price objective on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Truist Financial decreased their price objective on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday, August 7th. TD Cowen raised shares of DaVita from a “hold” rating to a “buy” rating and boosted their target price for the stock from $201.00 to $220.00 in a research report on Friday, August 7th. Finally, Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $221.75.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.